^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IFNL1 (Interferon Lambda 1)

    i
    Other names: IFNL1, Interferon Lambda 1, IL-29, IL29, Interleukin 29 (Interferon, Lambda 1), Interferon Lambda-1, Cytokine Zcyto21, Interleukin-29, IFN-Lambda-1, Interleukin 29, ZCYTO21
    Associations

    News

    Trials
    18d
    Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. (PubMed, Neuro Oncol)
    B7-H3 CAR T cells combined with ONC206 is a feasible and efficacious multi-agent approach against multiple DIPG models.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IFNL1 (Interferon Lambda 1)
    |
    JZP3507
    5ms
    Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. (PubMed, bioRxiv)
    This work offers a biologically-informed, clinically translatable strategy integrating small molecule therapeutics with CAR T cell therapy and support the development of multi-agent immunotherapy trials for children with DIPG and other high-grade brain and spinal cord tumors. B7-H3 CAR T cells are cytotoxic against preclinical DMG models.ONC206 causes metabolic apoptosis in preclinical DMG models.B7-H3 CAR T cells and ONC206 have combinatorial efficacy against DMG.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IFNL1 (Interferon Lambda 1)
    |
    JZP3507
    10ms
    Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. (PubMed, BMC Cancer)
    Compared to CA19-9, the mRNA biomarker panel, HELP-15, improved diagnostic performance in patients with RPC, particularly in those with normal CA19-9 levels.
    Journal • Liquid biopsy
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CLEC7A (C-Type Lectin Domain Containing 7A) • FOXP3 (Forkhead Box P3) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • IFNA1 (Interferon Alpha 1) • CA 19-9 (Cancer antigen 19-9) • IFNL1 (Interferon Lambda 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    over1year
    STRONG: Investigating the Combined Effects of Protein, Blueberries, and Exercise on Cardiovascular Health and Frailty in Older Nova Scotians (clinicaltrials.gov)
    P=N/A, N=240, Not yet recruiting, Nova Scotia Health Authority
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL32 (Interleukin 32) • TNFSF13B (TNF Superfamily Member 13b) • IFNA1 (Interferon Alpha 1) • IL22 (Interleukin 22) • MMP1 (Matrix metallopeptidase 1) • TSLP (Thymic Stromal Lymphopoietin) • IFNB1 (Interferon Beta 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • MMP3 (Matrix metallopeptidase 3) • TNFSF13 (TNF Superfamily Member 13) • TNFSF14 (TNF Superfamily Member 14)
    over1year
    Copy number variation and clinical response to chemotherapy and bevacizumab in the Czech metastatic colorectal cancer patients. (PubMed, Klin Onkol)
    In the pilot study, we found promising copy number variation biomarkers of bevacizumab response in FFPE samples of mCRC patients. The validation phase should be focused especially on the genes associated with angiogenesis (AGRN, MAPK8, ARHGAP22, LGALS13, LGALS4, ZFP36, and MYC), tumorigenesis (DVL1), and tumor proliferation (IFNL1, IFNL2, IFNL3, MAP3K10, and MAP4K1).
    Journal • Metastases
    |
    LGALS1 (Galectin 1) • MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • LGALS4 (Galectin 4) • AGRN (Agrin) • DVL1 (Dishevelled Segment Polarity Protein 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • MAPK8 (Mitogen-activated protein kinase 8) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    Avastin (bevacizumab)
    over1year
    BEAUTY: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CCR5 (C-C Motif Chemokine Receptor 5) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • HLA-B (Major Histocompatibility Complex, Class I, B) • NLRC5 (NLR Family CARD Domain Containing 5) • FOXP3 (Forkhead Box P3) • IKZF2 (IKAROS family zinc finger 2) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • ITGAX (Integrin Subunit Alpha X) • PRF1 (Perforin 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • TAP1 (Transporter 1) • CCR6 (C-C Motif Chemokine Receptor 6) • CEACAM8 (CEA Cell Adhesion Molecule 8) • DDX58 (DExD/H-Box Helicase 58) • HLA-C (Major Histocompatibility Complex, Class I, C) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • ITGB1 (Integrin Subunit Beta 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    Verzenio (abemaciclib)
    over1year
    Combined Molecular and Mechanistic Methods for Detection of Pressure Ulcers (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Linkoeping University
    New trial
    |
    VEGFA (Vascular endothelial growth factor A) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2RA (Interleukin 2 receptor, alpha) • IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4) • CHI3L1 (Chitinase 3-like 1) • CSF2 (Colony stimulating factor 2) • IL18 (Interleukin 18) • CCL8 (C-C Motif Chemokine Ligand 8) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IFNA1 (Interferon Alpha 1) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL17C (Interleukin 17C) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • IL21 (Interleukin 21) • IL22 (Interleukin 22) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • IL7 (Interleukin 7) • TSLP (Thymic Stromal Lymphopoietin) • IFNB1 (Interferon Beta 1) • IFNL1 (Interferon Lambda 1) • IL16 (Interleukin 16) • IL33 (Interleukin 33)
    almost2years
    Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence. (PubMed, Mol Immunol)
    Moreover, time to recurrence in breast cancer correlated positively with GRHL2 protein expression, indicating that GRHL2 is a tumor recurrence suppressor, consistent with its enhancement of interferon responses. These observations demonstrate that epithelial cell identity supports interferon responses in the context of cancer.
    Journal
    |
    IRF1 (Interferon Regulatory Factor 1) • IFNL1 (Interferon Lambda 1)
    |
    IRF1 expression
    almost2years
    New treatment alternatives for primary and metastatic colorectal cancer by an integrated transcriptome and network analyses. (PubMed, Sci Rep)
    In addition, this anti-metastatic treatment attenuated TGF-β dependent mesenchymal transition. Network analysis suggests IL-29A induces the JAK/STAT pathway in a preventive manner.
    Journal • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1) • IFNL1 (Interferon Lambda 1)
    almost2years
    Oral Antiviral Defense: Saliva- and Beverage-like Hypotonicity Dynamically Regulate Formation of Membraneless Biomolecular Condensates of Antiviral Human MxA in Oral Epithelial Cells. (PubMed, Cells)
    The spontaneous reassembly of GFP-MxA condensates in oral epithelial cells, even under continuous saliva-like hypotonicity, was slowed by the protein-phosphatase-inhibitor cyclosporin A (CsA) and by the K-channel-blocker tetraethylammonium chloride (TEA); this is suggestive of the involvement of the volume-sensitive WNK kinase-protein phosphatase (PTP)-K-Cl cotransporter (KCC) pathway in the regulated volume decrease (RVD) during condensate reassembly in oral cells. The present study identifies a novel subcellular consequence of hypotonic stress in oral epithelial cells, in terms of the rapid and dynamic changes in the structure of one class of phase-separated biomolecular condensates in the cytoplasm-the antiviral MxA condensates. More generally, the data raise the possibility that hypotonicity-driven stresses likely affect other intracellular functions involving liquid-liquid phase separation (LLPS) in cells of the oral mucosa.
    Journal
    |
    IFNL1 (Interferon Lambda 1)
    |
    cyclosporin A microemulsion
    almost2years
    Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology. (PubMed, Neurol Neuroimmunol Neuroinflamm)
    Our work demonstrates the utility of human cell microarray technology to detect known and discover unknown autoantibodies in human serum samples. Despite potential CIDP-associated autoantibodies (anti-LIF and anti-IFNL3) being identified, their clinical and pathogenic relevance needs to be elucidated in bigger cohorts.
    Journal
    |
    EPHA7 (EPH Receptor A7) • CNTN1 (Contactin 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • LIF (LIF Interleukin 6 Family Cytokine)
    almost2years
    The difference of immune microenvironment betweende novometastatic and non-metastatic microsatellite instability-high colorectal cancer (AACR 2024)
    There are significantly fewer cytotoxic and dendritic cells in late-stage MSI-H CRC, compared to early-stage MSI-H CRC, which is associated with decrease expression in JAK-STAT-IFN-γ- and antigen processing-related pathways.
    Microsatellite instability • MSi-H Biomarker • Metastases
    |
    MSI (Microsatellite instability) • IFNG (Interferon, gamma) • HMGB1 (High Mobility Group Box 1) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • GZMH (Granzyme H) • IFNL1 (Interferon Lambda 1) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    MSI-H/dMMR • IFNG expression
    |
    nCounter® PanCancer Immune Profiling Panel